Preclinical and clinical evidence of therapeutic agents for paclitaxel-induced peripheral neuropathy

Takehiro Kawashiri, Mizuki Inoue, Kohei Mori, Daisuke Kobayashi, Keisuke Mine, Soichiro Ushio, Hibiki Kudamatsu, Mayako Uchida, Nobuaki Egashira, Takao Shimazoe

Research output: Contribution to journalReview articlepeer-review

Abstract

Paclitaxel is an essential drug in the chemotherapy of ovarian, non-small cell lung, breast, gastric, endometrial, and pancreatic cancers. However, it frequently causes peripheral neuropathy as a dose-limiting factor. Animal models of paclitaxel-induced peripheral neuropathy (PIPN) have been established. The mechanisms of PIPN development have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory PIPN effects. This review summarizes the basic and clinical evidence for therapeutic or prophylactic effects for PIPN. In pre-clinical research, many reports exist of neuropathy inhibitors that target oxidative stress, inflammatory response, ion channels, transient receptor potential (TRP) channels, cannabinoid receptors, and the monoamine nervous system. Alternatively, very few drugs have demonstrated PIPN efficacy in clinical trials. Thus, enhancing translational research to translate pre-clinical research into clinical research is important.

Original languageEnglish
Article number8733
JournalInternational journal of molecular sciences
Volume22
Issue number16
DOIs
Publication statusPublished - Aug 2 2021

All Science Journal Classification (ASJC) codes

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Fingerprint

Dive into the research topics of 'Preclinical and clinical evidence of therapeutic agents for paclitaxel-induced peripheral neuropathy'. Together they form a unique fingerprint.

Cite this